1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: 760-603-2600
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Liver Biology and Pathobiology
You have full text access to this OnlineOpen article
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice†
Article first published online: 6 JUL 2005
DOI: 10.1002/hep.20783
Copyright © 2005 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Yu, X. X., Murray, S. F., Pandey, S. K., Booten, S. L., Bao, D., Song, X.-Z., Kelly, S., Chen, S., McKay, R., Monia, B. P. and Bhanot, S. (2005), Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology, 42: 362–371. doi: 10.1002/hep.20783
- †
Potential conflict of interest: Nothing to report.
Publication History
- Issue published online: 15 JUL 2005
- Article first published online: 6 JUL 2005
- Manuscript Accepted: 5 MAY 2005
- Manuscript Received: 16 DEC 2004
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis, Journal of Hepatology, 2012, 56, 3, 632
- 2, , , , , , , , , Anti-visceral obesity and antioxidant effects of powdered sea buckthorn (Hippophae rhamnoides L.) leaf tea in diet-induced obese mice, Food and Chemical Toxicology, 2011, 49, 9, 2370
- 3, , Cytochrome P450 2E1 and hyperglycemia-induced liver injury, Cell Biology and Toxicology, 2011, 27, 4, 285
- 4, , , Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet, European Journal of Pharmacology, 2011, 653, 1-3, 82
- 5, , , Inflammation in nonalcoholic steatohepatitis, Expert Review of Gastroenterology & Hepatology, 2011, 5, 2, 189
- 6, , Molecular mechanisms involved in hepatic steatosis and insulin resistance, Journal of Diabetes Investigation, 2011, 2, 3Direct Link:
- 7, , Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia, Clinical Lipidology, 2011, 6, 6, 675
- 8, , , , , , , Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice, Diabetologia, 2010, 54, 1, 146
- 9, , , , , , , , , , , , , Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22, Journal of Hepatology, 2010, 53, 2, 339
- 10, , , DGAT1, DGAT2 and PDAT Expression in Seeds and Other Tissues of Epoxy and Hydroxy Fatty Acid Accumulating Plants, Lipids, 2010, 45, 2, 145
- 11, , , Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies, Clinical Lipidology, 2010, 5, 6, 793
- 12, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites, Hepatology, 2010, 52, 2Direct Link:
- 13, , , Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents, Expert Opinion on Therapeutic Patents, 2010, 20, 1, 19
- 14, , Lipid oversupply, selective insulin resistance, and lipotoxicity: Molecular mechanisms, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010, 1801, 3, 252
- 15, , , , , , , , Liver gene expression in relation to hepatic steatosis and lipid secretion in two duck species, Animal Genetics, 2010, 41, 1Direct Link:
- 16, Molecular pathways and agents for lowering LDL-cholesterol in addition to statins, Pharmacology & Therapeutics, 2010, 126, 3, 263
- 17, , , Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications, Hepatology, 2010, 51, 2Direct Link:
- 18, Targeting energy expenditure via fuel switching and beyond, Diabetologia, 2010, 54, 2, 237
- 19, , , , , , , Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids, Hepatology, 2009, 50, 2Direct Link:
- 20
- 21, , , , , Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?, Expert Opinion on Investigational Drugs, 2008, 17, 7, 969
- 22, , , , , , , , , , Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis, Hepatology, 2008, 47, 2Direct Link:
- 23, , , , , Diacylglycerol acyltransferases: Potential roles as pharmacological targets, Pharmacology & Therapeutics, 2008, 118, 3, 295
- 24, , Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers, Expert Review of Cardiovascular Therapy, 2008, 6, 7, 1007
- 25, , , , , Hepatic and Adipose Tissue Depot-Specific Changes in Lipid Metabolism in Late-Onset Obese (LOB) Rats, Lipids, 2008, 43, 4, 313
- 26, , Hepatic triglyceride synthesis and nonalcoholic fatty liver disease, Current Opinion in Lipidology, 2008, 19, 3, 295
- 27
- 28
- 29, Nonalcoholic fatty liver disease: emerging mechanisms and consequences, Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 2, 128
- 30, , , Recent advances in nonalcholic fatty liver disease, Current Opinion in Gastroenterology, 2008, 24, 3, 320
- 31, , , , Regulation of Hepatic Lipogenesis by the Transcription Factor XBP1, Science, 2008, 320, 5882, 1492
- 32, Therapy for Nonalcoholic Fatty Liver Disease, Journal of Clinical Gastroenterology, 2008, 42, 4, 332
- 33, , , , , , , , , A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 2007, 46, 4Direct Link:
- 34, , , , Antisense and small-molecule modulation of diacylglycerol acyltransferase, Expert Opinion on Therapeutic Patents, 2007, 17, 11, 1331
- 35, , , , , , , , , , , , Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver, Cell Metabolism, 2007, 6, 1, 69
- 36, , Effects of cysteine-containing compounds on biosynthesis of triacylglycerol and cholesterol and anti-oxidative protection in liver from mice consuming a high-fat diet, British Journal of Nutrition, 2007, 99, 01
- 37, , , , , , , , Fatty acid modulators for the treatment of diabesity, Drug Discovery Today: Therapeutic Strategies, 2007, 4, 2, 129
- 38, , , , Fine-Tuning of ENA®Gapmers as Antisense Oligonucleotides for Sequence-Specific Inhibition, Oligonucleotides, 2007, 17, 3, 291
- 39, , , Good fat/bad fat, Hepatology, 2007, 45, 6Direct Link:
- 40, , , , , , , , , , Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis, Hepatology, 2007, 45, 6Direct Link:
- 41, , , , , , Reduction of Hepatosteatosis and Lipid Levels by an Adipose Differentiation-Related Protein Antisense Oligonucleotide, Gastroenterology, 2007, 132, 5, 1947
- 42, , Thermogenic and metabolic antiobesity drugs: rationale and opportunities, Diabetes, Obesity and Metabolism, 2007, 9, 3Direct Link:
- 43, An editor's look-back, Hepatology, 2006, 43, S1Direct Link:
- 44, , , , , , , , Direct Comparison ofIn VivoAntisense Activity of ENA Oligonucleotides Targeting PTP1B mRNA with That of 2'-O-(2-Methoxy)ethyl-Modified Oligonucleotides, Oligonucleotides, 2006, 16, 3, 253
- 45, , , , Effect of niacin on lipoproteins and atherosclerosis, Future Lipidology, 2006, 1, 5, 549
- 46, , , , , , , , , , , , , , , , , miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metabolism, 2006, 3, 2, 87
- 47, , , , Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery,Direct Link: